<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684812</url>
  </required_header>
  <id_info>
    <org_study_id>2012-000343-26</org_study_id>
    <nct_id>NCT02684812</nct_id>
  </id_info>
  <brief_title>Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage.</brief_title>
  <acronym>ULTRA</acronym>
  <official_title>Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage. A Prospective, Randomized, Multicenter Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stichting Nuts Ohra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, randomized, open-label trial with blinded endpoint
      (PROBE) assessment. Adult patients with the diagnosis of non-traumatic SAH, as proven by
      computed tomography (CT) within 24 hours after the onset of headache, will be randomly
      assigned to the treatment group or the control group. Patients in the treatment group will
      receive standard treatment with the addition of a bolus of TXA (1 g intravenously)
      immediately after randomization, followed by continuous infusion of 1 g per 8 hours until the
      start of aneurysm treatment, or a maximum of 24 hours after the start of medication. Patients
      in the control group will receive standard treatment without TXA. The primary outcome measure
      is favorable functional outcome, defined as a score of 0 to 3 on the modified Rankin Scale
      (mRS), at 6 months after SAH. Primary outcome will be determined by a trial nurse blinded for
      treatment allocation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 50% of all patients with a subarachnoid hemorrhage (SAH) die due to the
      hemorrhage or subsequent complications. There are several major causes for this course, such
      as in-hospital rebleed in 21.5% which most frequently occurs within the first 6 hours after
      the primary hemorrhage (&quot;ultra-early rebleed&quot;). A major part of the patients with a rebleed
      die during hospital admission and when they survive, they develop more severe cognitive
      dysfunctions. Reducing the rebleeds by ultra-early administration of tranexamic acid (TXA)
      could be a major factor in improving the functional outcome after SAH.

      To evaluate whether SAH patients treated by state-of-the-art SAH management with additional
      ultra-early and short term TXA administration have a significantly higher percentage of
      favourable outcome after six months (score 0-3 on the Modified Rankin Scale) compared to the
      group treated by up-to-date SAH management without additional TXA.

      To evaluate whether: 1) TXA reduces in-hospital rebleeds and case fatalities; 2) TXA causes
      more ischemic stroke 3) TXA causes more complications (such as thromboembolic events,
      hydrocephalus, extracranial thrombosis or hemorrhagic complications) during treatment,
      admission and follow-up; 4) there is a difference in causes of poor outcome between groups;
      5) there is a difference in discharge locations between groups; 6) there is an association
      between the time between hemorrhage and TXA administration and outcome; 7) TXA increases
      (micro)infarctions after endovascular treatment; 8) TXA reduces health-care costs between
      discharge and six months after hemorrhage; 9) TXA improves quality of life at six months
      after hemorrhage; 10) there are differences in rebleed rates and outcome between genders or
      groups with different WFNS scores at admission.

      Multicenter, prospective, randomized, open label treatment with blind endpoint assessment.

      Adult patients (18 years and older) included within 24 hours after SAH. Group one: standard
      treatment with additional administration of 1 g TXA intravenously in ten minutes, immediately
      after the diagnosis SAH, succeeded by continuous infusion of 1 g per 8 hours until a maximum
      of 24 hours. Group two: standard treatment with no TXA administration. Both groups undergo a
      standardized and validated interview at discharge and six months after hemorrhage to assess
      the modified Rankin Scale score, and both groups receive a questionnaire to evaluate
      health-care costs and quality of life.

      Primary: modified Rankin Scale score after six months, dichotomized into favourable and
      unfavourable outcome. Secondary: rebleed and case fatality rate, complications during the
      first six months after hemorrhage, (micro)infarctions at MR imaging after endovascular
      treatment, health-care costs from discharge until six months, quality of life at six months
      and differences in rebleed rates and outcome between genders or WFNS score at admission.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness: Subjects are randomly allocated to ultra-early TXA therapy or standard
      treatment. Complications are minor and the expected benefit is large compared with separate
      studies done with antifibrinolytic medications. In these studies, the safety of the use of
      these medications in this study population is confirmed. In this patient group there are
      adequate, disoriented and comatose patients on admission, so a part of the studied patients
      are incapacitated when undergoing the study. To extrapolate the conclusions of this study to
      clinical protocols it is necessary to include patients with a SAH in all different severity
      grades. Weighing carefully the benefits versus the burden and risks, it is assumed that
      patients will benefit from ultra-early TXA administration with minimal burden during therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale (mRS)</measure>
    <time_frame>six months</time_frame>
    <description>Good (mRS 0-3) and Poor (mRS 4-6)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Date and cause of death</measure>
    <time_frame>Maximum six month</time_frame>
    <description>Assessment of cause of death by a committee (intensive care/neurosurgeon)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause of poor outcome</measure>
    <time_frame>six months</time_frame>
    <description>Assessment of which events during hospital admission led to a poor outcome defined as mRS 4 and 5 by a committee (intensive care/neurosurgeon)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rebleed and time interval after first hemorrhage</measure>
    <time_frame>six months</time_frame>
    <description>The time interval between the initial hemorrhage and occurence of a recurrent bleeding will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic events during endovascular treatment</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Complications during endovascular treatment will be recorded (ie occurence of clotting in one of the vessels)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke (Dealyed cerebral ischemia)</measure>
    <time_frame>14-20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracranial thrombosis</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hydrocephalus and treatment modality</measure>
    <time_frame>six months</time_frame>
    <description>Occurence of a hydrocephalus will be recorded and which treatment modality is used to treat the hydrocephalus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic complications (intra- and extracranial)</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time interval from last hemorrhage to first TXA administration</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge location</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarctions on MR imaging at six months after endovascular treatment</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-care costs between discharge and six months after hemorrhage</measure>
    <time_frame>three and six months</time_frame>
    <description>Questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life at six months after hemorrhage</measure>
    <time_frame>six months</time_frame>
    <description>Questionnaire (EQ-5D)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">950</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible subjects are randomly assigned to immediate administration of TXA (1 g i.v.) after a diagnosis of SAH, as confirmed by CT-scan of the brain, continued by continuous infusion of 1 g per 8 hours to a maximum of 24 hours after start of medication. A maximum of 4 g TXA (1 g bolus + 3x 1 g continuous infusion) can be administered to one patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Treatment until aneurysm treatment or maximum dosage of 4 gram</description>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission to one of the study centers or their referring hospitals

          -  CT-confirmed SAH with most recent ictus less than 24 hours ago Definition:
             subarachnoid hemorrhage is a bleeding pattern on computed tomography with hyperdensity
             in the basal cisterns and/or Sylvian or interhemipheric fissures or a intraparenchymal
             hyperdensity consistent with a hematoma from an anterior, a pericallosal, a posterior
             or a middle cerebral artery aneurysm.

        Exclusion Criteria:

          -  No proficiency of the Dutch or English language

          -  No loss of consciousness after the hemorrhage with WFNS grade 1 or 2 on admission in
             combination with a perimesencephalic hemorrhage Definition: on CT examination presence
             of hyperdensities exclusively in the basal cisterns maximal extending to the proximal
             part of the Sylvian fissure or posterior part of the interhemispheric fissure, without
             evidence for intracerebral or intraventricular haemorrhage (except slight
             sedimentation)

          -  Bleeding pattern on CT compatible with a traumatic SAH

          -  Treatment for deep vein thrombosis or pulmonary embolism

          -  History of a blood coagulation disorder (a hypercoagulability disorder)

          -  Pregnancy checked with a pregnancy test in women in their childbearing period

          -  History of severe renal (serum creatinin &gt;150 mmol/L)

          -  History of severe liver failure (AST &gt; 150 U/l or ALT &gt; 150 U/l or AF &gt; 150 U/l or
             Î³-GT &gt; 150 U/l)

          -  Imminent death within 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William P Vandertop, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurosurgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dagmar Verbaan, PhD</last_name>
    <phone>020-5669111</phone>
    <email>d.verbaan@amc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>William P Vandertop, PhD MD</last_name>
    <phone>020-5669111</phone>
    <email>w.p.vandertop@amc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rene Post, MD</last_name>
      <email>r.post@amc.nl</email>
    </contact>
    <investigator>
      <last_name>Rene Post, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dagmar Verbaan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.ultrastudie.com</url>
    <description>Trial website</description>
  </link>
  <results_reference>
    <citation>Germans MR, Post R, Coert BA, Rinkel GJ, Vandertop WP, Verbaan D. Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials. 2013 May 16;14:143. doi: 10.1186/1745-6215-14-143.</citation>
    <PMID>23680226</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2016</study_first_posted>
  <last_update_submitted>February 12, 2016</last_update_submitted>
  <last_update_submitted_qc>February 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>R. Post</investigator_full_name>
    <investigator_title>Drs.</investigator_title>
  </responsible_party>
  <keyword>antifibrinolytic therapy</keyword>
  <keyword>recurrent bleeding</keyword>
  <keyword>tranexamic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

